Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Plantar Fasciitis Treatment Market by Type (Medication Therapy, Orthotics, Shockwave Therapy, Surgery, Others) and by End User (Hospitals, Ambulatory Surgical Center, Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A10452

Pages: NA

Charts: NA

Tables: NA

Planter fasciitis is a common cause of foot pain caused by a repetitive strain injury. It affects the heel portion of the foot and results into tenderness of the sole. It is a type of muscle sole inflammation. It is prevalent among the people who stand on hard surface for long time. Foot stretches activities help individual to get relief from the pain of planter fasciitis. Planter fasciitis is caused when the strong band of tissue supports arch of foot become irritated and inflamed, this hurts the foot during walking. The global planter fasciitis treatment market is experiencing significant growth, and will grow considerably in the next few years. Orthotics is one of the commonly used product type of planter fasciitis, which is considered as the largest contributing product in the market growth. Orthotics are mostly prescribed by physicians for the treatment of planter fasciitis and provide various benefits including quick pain relief and low cost.

Planter fasciitis is common in individuals aged between 40 and 60 years, especially in women. The American Academy of Orthopedic Surgeons provides various guidelines on choosing the right foot wear, which helps to relieve plantar fasciitis.

COVID-19 Scenario Analysis: 

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future. To prevent the spread of COVID-19, people are maintaining social distancing. Thus, they are avoiding to take the treatment of the planter fasciitis, which will directly impact on the market growth. The affect will resulted not only on the market growth but also on the patients suffering from planter fasciitis.     

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

According to the National center for health statistics (NCHS), globally 2 million people suffer from planter fasciitis every year. National Institute for Health and Care Excellence (NIHCE), reported that 80% cases suffering from heel pain and 10% of individuals will experience this problem during their lifetime. Due to the increasing number of advanced treatment related to planter fasciitis and rising number of obese individuals, North America dominates the overall market and it is considered as the largest contributor to the development of the planter fasciitis treatment market. In 2018, the U.S. FDA reduced the timeline period of clinical trial phase-IIb study of injectable Amino Fix for the treatment of planter fasciitis from two years to one year.  

The driving factor such as, availability of technologically advanced product, increasing the large number of treatment, inactive lifestyle of individual, rising geriatric population, rising prevalence of obesity, and rising adoption of orthotic treatment, drive the market growth of plantar fasciitis treatment market. Restraining factor such as, Increasing cost of raw material and declining high cost of product, lack of awareness about treatment, may hinder the growth of plantar fasciitis treatment market.

New product launches to flourish the market:

Manufacturers focus on producing new product with more improved capabilities that fuel the growth of plantar fasciitis treatment market and help individual to get relief from pain. In 2018, the U.S. FDA announced that they reduced the timeline period of clinical trial phase-IIb study of injectable Amino Fix for the treatment of planter fasciitis from two year to one year. For relieving foot pain, various industries manufacture types of orthotic device pain such as Ankle foot orthoses and knee-ankle foot orthoses, and it is the most effective method for those individuals who are suffering from the discomfort of planter fasciitis. In 2018, Revance Therapeutics, Inc. launched DaxibotulinumtoxinA for injection that is used to treat planter fasciitis. In 2017 Wiivv, launched custom-feet footwear, this product helps to relieve individual foot pain.  

Key benefits of the report:

  • This study presents the analytical depiction of the global plantar fasciitis treatment market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global plantar fasciitis treatment market share.
  • The current market is quantitatively analyzed to highlight the global plantar fasciitis treatment market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed global plantar fasciitis treatment market analysis based on competitive intensity and how the competition will take shape in coming years. 

Questions answered in the plantar fasciitis treatment Market research report:

  • Which are the leading market players active in the plantar fasciitis treatment market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the plantar fasciitis treatment market?
  • What are the projections for the future that would help in taking further strategic steps?

Key Market Segments

  • By Type
    • Medication Therapy
    • Orthotics
    • Shockwave Therapy
    • Surgery
    • Others
  • By End User
    • Hospitals
    • Ambulatory Surgical Center
    • Clinics
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA


Key Market Players

  • Sanofi, Group (Dr. Scholl’s),
  • GlaxoSmithKline Plc.
  • Bayer
  • Bauerfeid AG,
  • Pfizer, Inc.
  • A. Algeo Ltd.
  • Hanger Inc.,
  • Otto bock SE & Co.,
  • KGaA (Otto bock Holding).
  • Superfeet Worldwide, Inc.,
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: PLANTAR FASCIITIS TREATMENT MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Medication Therapy

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Orthotics

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Shockwave Therapy

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Surgery

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: PLANTAR FASCIITIS TREATMENT MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Ambulatory Surgical Center

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Clinics

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: PLANTAR FASCIITIS TREATMENT MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Plantar Fasciitis Treatment Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By End User
      • 6.2.6. Canada Plantar Fasciitis Treatment Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By End User
      • 6.2.7. Mexico Plantar Fasciitis Treatment Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By End User
    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Plantar Fasciitis Treatment Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By End User
      • 6.3.6. Germany Plantar Fasciitis Treatment Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By End User
      • 6.3.7. Italy Plantar Fasciitis Treatment Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By End User
      • 6.3.8. Spain Plantar Fasciitis Treatment Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By End User
      • 6.3.9. UK Plantar Fasciitis Treatment Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By End User
      • 6.3.10. Russia Plantar Fasciitis Treatment Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By End User
      • 6.3.11. Rest Of Europe Plantar Fasciitis Treatment Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By End User
    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Plantar Fasciitis Treatment Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By End User
      • 6.4.6. Japan Plantar Fasciitis Treatment Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By End User
      • 6.4.7. India Plantar Fasciitis Treatment Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By End User
      • 6.4.8. South Korea Plantar Fasciitis Treatment Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By End User
      • 6.4.9. Australia Plantar Fasciitis Treatment Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By End User
      • 6.4.10. Thailand Plantar Fasciitis Treatment Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By End User
      • 6.4.11. Malaysia Plantar Fasciitis Treatment Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By End User
      • 6.4.12. Indonesia Plantar Fasciitis Treatment Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By End User
      • 6.4.13. Rest of Asia Pacific Plantar Fasciitis Treatment Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By End User
    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Plantar Fasciitis Treatment Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By End User
      • 6.5.6. South Africa Plantar Fasciitis Treatment Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By End User
      • 6.5.7. Saudi Arabia Plantar Fasciitis Treatment Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By End User
      • 6.5.8. UAE Plantar Fasciitis Treatment Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By End User
      • 6.5.9. Argentina Plantar Fasciitis Treatment Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By End User
      • 6.5.10. Rest of LAMEA Plantar Fasciitis Treatment Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By End User
  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. GlaxoSmithKline Plc.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Bayer

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Pfizer, Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Sanofi, Group (Dr. Scholl’s),

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Superfeet Worldwide, Inc.,

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. A. Algeo Ltd.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Hanger Inc.,

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Bauerfeid AG,

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Otto Bock SE And Co.,

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. KGaA (Otto Bock Holding).

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET FOR MEDICATION THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET FOR ORTHOTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET FOR SHOCKWAVE THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET FOR SURGERY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET FOR AMBULATORY SURGICAL CENTER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET FOR CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA PLANTAR FASCIITIS TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 16. U.S. PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 17. U.S. PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 18. CANADA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 19. CANADA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 21. MEXICO PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE PLANTAR FASCIITIS TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 24. EUROPE PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 26. FRANCE PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 28. GERMANY PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. ITALY PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 30. ITALY PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 32. SPAIN PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. UK PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 34. UK PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 36. RUSSIA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 38. REST OF EUROPE PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC PLANTAR FASCIITIS TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 41. ASIA-PACIFIC PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. CHINA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 43. CHINA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 45. JAPAN PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. INDIA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 47. INDIA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 49. SOUTH KOREA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 51. AUSTRALIA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 53. THAILAND PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 55. MALAYSIA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 57. INDONESIA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. REST OF ASIA PACIFIC PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA PLANTAR FASCIITIS TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 62. LAMEA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 64. BRAZIL PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH AFRICA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 68. SAUDI ARABIA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 69. UAE PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 70. UAE PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 72. ARGENTINA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA PLANTAR FASCIITIS TREATMENT, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 74. REST OF LAMEA PLANTAR FASCIITIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 75. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 76. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 77. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 78. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 79. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. BAYER: KEY EXECUTIVES
  • TABLE 81. BAYER: COMPANY SNAPSHOT
  • TABLE 82. BAYER: OPERATING SEGMENTS
  • TABLE 83. BAYER: PRODUCT PORTFOLIO
  • TABLE 84. BAYER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 86. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 87. PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 88. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 89. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90. SANOFI, GROUP (DR. SCHOLL’S),: KEY EXECUTIVES
  • TABLE 91. SANOFI, GROUP (DR. SCHOLL’S),: COMPANY SNAPSHOT
  • TABLE 92. SANOFI, GROUP (DR. SCHOLL’S),: OPERATING SEGMENTS
  • TABLE 93. SANOFI, GROUP (DR. SCHOLL’S),: PRODUCT PORTFOLIO
  • TABLE 94. SANOFI, GROUP (DR. SCHOLL’S),: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 95. SUPERFEET WORLDWIDE, INC.,: KEY EXECUTIVES
  • TABLE 96. SUPERFEET WORLDWIDE, INC.,: COMPANY SNAPSHOT
  • TABLE 97. SUPERFEET WORLDWIDE, INC.,: OPERATING SEGMENTS
  • TABLE 98. SUPERFEET WORLDWIDE, INC.,: PRODUCT PORTFOLIO
  • TABLE 99. SUPERFEET WORLDWIDE, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 100. A. ALGEO LTD.: KEY EXECUTIVES
  • TABLE 101. A. ALGEO LTD.: COMPANY SNAPSHOT
  • TABLE 102. A. ALGEO LTD.: OPERATING SEGMENTS
  • TABLE 103. A. ALGEO LTD.: PRODUCT PORTFOLIO
  • TABLE 104. A. ALGEO LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105. HANGER INC.,: KEY EXECUTIVES
  • TABLE 106. HANGER INC.,: COMPANY SNAPSHOT
  • TABLE 107. HANGER INC.,: OPERATING SEGMENTS
  • TABLE 108. HANGER INC.,: PRODUCT PORTFOLIO
  • TABLE 109. HANGER INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. BAUERFEID AG,: KEY EXECUTIVES
  • TABLE 111. BAUERFEID AG,: COMPANY SNAPSHOT
  • TABLE 112. BAUERFEID AG,: OPERATING SEGMENTS
  • TABLE 113. BAUERFEID AG,: PRODUCT PORTFOLIO
  • TABLE 114. BAUERFEID AG,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. OTTO BOCK SE AND CO.,: KEY EXECUTIVES
  • TABLE 116. OTTO BOCK SE AND CO.,: COMPANY SNAPSHOT
  • TABLE 117. OTTO BOCK SE AND CO.,: OPERATING SEGMENTS
  • TABLE 118. OTTO BOCK SE AND CO.,: PRODUCT PORTFOLIO
  • TABLE 119. OTTO BOCK SE AND CO.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. KGAA (OTTO BOCK HOLDING).: KEY EXECUTIVES
  • TABLE 121. KGAA (OTTO BOCK HOLDING).: COMPANY SNAPSHOT
  • TABLE 122. KGAA (OTTO BOCK HOLDING).: OPERATING SEGMENTS
  • TABLE 123. KGAA (OTTO BOCK HOLDING).: PRODUCT PORTFOLIO
  • TABLE 124. KGAA (OTTO BOCK HOLDING).: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PLANTAR FASCIITIS TREATMENT MARKET
  • FIGURE 3. SEGMENTATION PLANTAR FASCIITIS TREATMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PLANTAR FASCIITIS TREATMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPLANTAR FASCIITIS TREATMENT MARKET
  • FIGURE 11. PLANTAR FASCIITIS TREATMENT MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. PLANTAR FASCIITIS TREATMENT MARKET FOR MEDICATION THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. PLANTAR FASCIITIS TREATMENT MARKET FOR ORTHOTICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. PLANTAR FASCIITIS TREATMENT MARKET FOR SHOCKWAVE THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. PLANTAR FASCIITIS TREATMENT MARKET FOR SURGERY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. PLANTAR FASCIITIS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. PLANTAR FASCIITIS TREATMENT MARKET SEGMENTATION, BY BY END USER
  • FIGURE 18. PLANTAR FASCIITIS TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. PLANTAR FASCIITIS TREATMENT MARKET FOR AMBULATORY SURGICAL CENTER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. PLANTAR FASCIITIS TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. PLANTAR FASCIITIS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 26. COMPETITIVE DASHBOARD
  • FIGURE 27. COMPETITIVE HEATMAP: PLANTAR FASCIITIS TREATMENT MARKET
  • FIGURE 28. TOP PLAYER POSITIONING, 2024
  • FIGURE 29. GLAXOSMITHKLINE PLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 32. BAYER: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. BAYER: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. BAYER: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. PFIZER, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. PFIZER, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. SANOFI, GROUP (DR. SCHOLL’S),: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. SANOFI, GROUP (DR. SCHOLL’S),: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. SANOFI, GROUP (DR. SCHOLL’S),: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. SUPERFEET WORLDWIDE, INC.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. SUPERFEET WORLDWIDE, INC.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. SUPERFEET WORLDWIDE, INC.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. A. ALGEO LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. A. ALGEO LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. A. ALGEO LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. HANGER INC.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. HANGER INC.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. HANGER INC.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. BAUERFEID AG,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. BAUERFEID AG,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. BAUERFEID AG,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. OTTO BOCK SE AND CO.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. OTTO BOCK SE AND CO.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. OTTO BOCK SE AND CO.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. KGAA (OTTO BOCK HOLDING).: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. KGAA (OTTO BOCK HOLDING).: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. KGAA (OTTO BOCK HOLDING).: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Plantar Fasciitis Treatment Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue